The importance of early insulin secretion and its impact on glycaemic regulation

International Journal of Obesity

Volumn 24, Issue , 2000, Pages S32-S37

  Garber, A J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Prandial glucose regulation; Repaglinide; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON; GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; TROGLITAZONE;

DRUG EFFICACY; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

BLOOD GLUCOSE; CARBAMATES; DIABETES MELLITUS, NON-INSULIN-DEPENDENT; DRUG THERAPY, COMBINATION; EATING; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; PIPERIDINES; TIME FACTORS;

EID: 0033803844     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0801423     Document Type: Article

References (39)

1. Home PD. Rapid-acting insulin secretagogues: a clinical need? Exp Clin Endocrinol Diabetes 1999; 107: S115-S119.
2. Melander A, Donnelly R, Rydberg T. Is there a concentration-effect relationship for sulphonylureas? Clin Pharmacokinet 1998; 34: 181-188.
3. Polonsky KS, Sturis J, Bell GI. Review Articles: seminars in medicine of the Beth Israel Hospital, Boston: non-insulin-dependent diabetes mellitus-a genetically programmed fail-ure of the beta cell to compensate for insulin resistance. New Engl J Med 1996; 334: 777-783.
4. Poitout V, Robertson RP. An integrated view of beta-cell dysfunction in type-II diabetes. AnnuRevMed 1996; 47: 69-83.
5. Kruszynska YT, Home PD. Night-time metabolic changes in normal subjects in the absence of the dawn phenomenon. Diabete Metab 1988; 14: 437-442.
6. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E. Abnormal patterns of insulin secretion in non-insulin dependent diabetes mellitus. New Engl J Med 1988; 318: 1231-1239.
7. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Reilly J, Gerich J. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. New Engl J Med 1992; 326: 22-29.
8. Crepaldi G, Del Prato S. What therapy do our NIDDM patients need? Insulin releasers. Diabetes Res Clin Pract 1995; 28: S159-S165.
9. Owens DR, Luzio SD, Coates PA. Insulin secretion and sensitivity in newly diagnosed NIDDM Caucasians in the UK. Diabetic Med 1996; 13: S19-S24.
10. Gerich JE. Metabolic abnormalities in impaired glucose tolerance. Metabolism 1997; 46: 40-43.
11. Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL, Porte D. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol 1976; 42: 222-229.
12. Coates PA, Ollerton RL, Luzio SD, Ismail I, Owens DR. A glimpse of the ‘natural history’ of established Type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract 1994; 26: 177-187.
13. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1989; 1(8651): 1356-1359.
14. Dowse GK, Zimmet PZ, Collins VR. Insulin levels and the natural history of glucose intolerance in Nauruans. Diabetes 1996; 45: 1367-1372.
15. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycaemia in NIDDM. Diabetes 1990; 39: 1381-1390.
16. Markovic TP, Furler SM, Jenkins AB, Campbell LV, Kraegen EW, Chisholm DJ. Importance of early insulin levels on prandial glycaemic responses and thermogenesis in non-insu-lin-dependent diabetes mellitus. Diabetic Med 1995; 12: 523-530.
17. Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti MC, Avogaro A, Tiengo A, Del Prato S. Restoration of early rise in plasma insulin levels improves the glucose tolerance of Type 2 diabetic patients. Diabetes 1999; 48: 99-105.
18. Bruce DG, Chisholm DJ, Storlien LH, Borkman M, Kraegen EW. Meal-time intranasal insulin delivery in Type 2 diabetes. Diabetic Med 1991; 8: 366-370.
19. Oliver S, Ahmad S. Pharmacokinetics and bioavailability of repaglinide, a new oral antidiabetic agent for patients with Type 2 diabetes (NIDDM). Diabetologia 1997; 40(Suppl 1): A320.
20. Owens DR. Repaglinide-prandial glucose regulator: a new class of oral antidiabetic drug. Diabetic Med 1998; 15(Suppl 4): S28-S36.
21. Hatorp V, Hasslacher C, Clauson P. Pharmacokinetics of repaglinide in Type 2 diabetes patients with and without renal impairment. Diabetologia 1999; 42(Suppl 1): A242.
22. Bakkali-Nadi A, Mailaisse-Lagae F, Malaisse WJ. Insulino-tropic action of meglitinide analogues; concentration-reponse relationship and nutrient dependency. Diabetes Res 1994; 27: 81-87.
23. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345-351.
24. Van Gaal LF, Van Acker KL, Damsbo P, De Leeuw IH. Metabolic effects of repaglinide, a new oral hypoglycaemic agent in therapy-naïve Type 2 diabetics. Diabetologia 1995; 38(Suppl 1): A43.
25. Goldberg RB, Einhorn D, Luca CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG. A randomized placebo-controlled trial of repaglinide in the treatment of Type 2 diabetes. Diabetes Care 1998; 21: 1897-1903.
26. Jovanovic L, Dailey G, Huang WC, Strange P, Goldstein BJ. Repaglinide in Type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000; 40: 49-57.
27. Landgraf R, Frank M, Bauer C, Leyck Dieken M. Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with Type 2 diabetes. Int J Obes Relat Metab Disord 2000; 24(Suppl 3): S38-S44.
28. Wolffenbuttel BH, Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of Type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 1999; 22: 463-467.
29. Marbury T, Huang WC, Strange P, Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999; 43: 155-166.
30. Landgraf R, Bilo HJ, Muller PG. A comparison of repaglinide and glibenclamide in the treatment of Type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 1999; 55: 165-171.
31. Dejgaard A, Madsbad S, Kilhovd B, Lager I, Mustajoki P. Repaglinide compared to glipizide in the treatment of Type 2 diabetic patients. Diabetologia 1998; 41(Suppl 1): A236.
32. Smedegaard Kristensen J, Brown Frandsen K, Bayer T, Müller PG. Repaglinide treatment is associated with significantly less severe hypoglycaemic events compared to sulphonylureas. Diabetologia 1999; 42(Suppl 1): A4.
33. Moses R, Gomis R, Brown Frandsen K, Clauson P. The efficacy and safety of repaglinide used as a flexible prandial glucose regulator in patients with Type 2 diabetes: a multicentre, randomised, placebo-controlled, double-blind study. Diabetic Med 1999; 16(Suppl 1): S95.
34. Damsbo P, Marbury TC, Hatorp V, Clauson P, Müller PG. Flexible prandial glucose regulation with repaglinide in patients with Type 2 diabetes. Diabetes Res Clin Pract 1999; 45: 31-39.
35. Feinglos MN, Bethel MA. Treatment of Type 2 diabetes mellitus. Med Clin North Am 1998; 82: 757-790.
36. Sparano N, Seaton TL. Troglitazone in Type II diabetes mellitus. Pharmacotherapy 1998; 18: 539-548.
37. Emilien G, Maloteaux J-M, Ponchon M. Pharmacological management of diabetes: recent progress and future perspective in daily drug treatment. Pharmacol Ther 1999; 81: 37-51.
38. Raskin P, Kennedy F, Woo V, Jain R, Müller PG. A multicenter, randomized study of the therapeutic effect of repaglinide combined with troglitazone in subjects with Type 2 diabetes. Diabetes 1999; 48(Suppl 1): A107.
39. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, Donnelly T, Moffitt P, Hopkins H. Effect of repagli-nide addition to metformin monotherapy on glycemic control in patients with Type 2 diabetes. Diabetes Care 1999; 22: 119-124.